A 31-year-old woman presented with acute right abdominal pain of 5 hours' duration. Imaging studies showed obstruction and dilatation of the inferior vena cava. The patient suffered a cardiopulmonary arrest; during emergency surgery 230 g of "clot-like" material was removed from the inferior vena cava, right heart, and pulmonary arteries. The patient died the following day. Pathologic examination of the resected material showed a biphasic synovial sarcoma. At autopsy only a minimal amount of residual tumor was present in the wall of the inferior vena cava. Tumor embolization from another site was excluded on the basis of radiologic studies and autopsy findings. This appears to be the second reported case of intravascular synovial sarcoma and the first reported case with a fatal outcome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0046-8177(93)90021-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Soft tissue sarcomas (STS) are rare, heterogeneous neoplasms often not optimally managed by teams without sarcoma expertise. Between 40 % and 50 % of primary resections for extremity sarcomas occur without prior biopsy, resulting in inadequate excisions, termed "unplanned resections" or "whoops surgery."
Objective: To determine the rate of unplanned resections in extremity STS referred to a high-volume sarcoma center and evaluate their impact on oncological outcomes.
Single stage combined approach total en-bloc spondylectomy of L1 and L2 vertebrae for primary spinal and paraspinal synovial sarcoma.
Br J Neurosurg
March 2025
Department of Surgical Oncology, Cancer Institute- Women India Association (WIA), Chennai, India.
Background: Spinal synovial sarcomas are the rarest of synovial soft tissue sarcomas. Limited data exist about their epidemiology, management, and oncological and functional outcomes. Multi-segment total en-bloc spondylectomy (TES) is challenging and requires appropriate reconstruction to achieve satisfactory oncological and functional outcomes.
View Article and Find Full Text PDFRedefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial.
ESMO Open
March 2025
Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address:
Background: We report the results of the pre-planned secondary analysis of radiologic responses (RRs) of ISG-STS 1001, a randomized trial comparing anthracycline + ifosfamide (AI) versus histology-tailored (HT) neoadjuvant chemotherapy for primary localized high-risk soft-tissue sarcomas of the extremities and trunk wall.
Patients And Methods: Patients with undifferentiated pleomorphic sarcoma (UPS), leiomyosarcoma (LMS), malignant peripheral nerve sheath tumor, synovial sarcoma or myxoid liposarcoma (MLPS) were randomized, whereas patients with myxofibrosarcoma, pleomorphic liposarcoma, pleomorphic rhabdomyosarcoma or unclassified sarcoma were included in the observational arm (O) and treated with AI. Patients with UPS, LMS or MLPS needing concurrent preoperative radiotherapy were included in O.
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies.
Cell Rep Med
February 2025
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston 77030, TX, USA.
IMCnyeso, an immune mobilizing monoclonal T cell receptor against cancer (ImmTAC) bispecific (New York esophageal squamous cell carcinoma [NY-ESO]×CD3) T cell engager, targets an NY-ESO-1/L-antigen family member-1 isoform A (LAGE-1A) peptide presented by histocompatibility leukocyte antigen (HLA)-A∗02:01. In this phase 1 study, 28 HLA-A∗02:01+ patients with advanced NY-ESO-1/LAGE-1A-positive advanced tumors (n = 28) receive IMCnyeso weekly intravenously (dose range: 3-300 μg; 7 dose-escalation cohorts). The primary objective is to identify the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D); additional objectives include preliminary anti-tumor activity, pharmacokinetics, immunogenicity, and pharmacodynamic changes.
View Article and Find Full Text PDFHeart-breaking tumours: a case series of malignant pericardial effusion.
Eur Heart J Case Rep
March 2025
Department of Cardiology, Walsall Healthcare NHS Trust, Walsall, UK.
Background: Malignant pericardial effusions are often linked to metastases from solid tumours, such as those in the lung or breast, or haematological diseases. Primary cardiac tumours are rare, occurring in only 0.02% of cases, with pericardial tumours comprising 6.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!